Stockreport

Phanes Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF The clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the treatment of small cell lung cancer (SCLC), large cell neuroendocr [Read more]